Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants.
Biological & pharmaceutical bulletin | 2017-01-01 | PMID 28674251
Mukai Yuji, Narita Masayuki, Akiyama Erika and 6 more
